- Report
- January 2023
- 217 Pages
Global
From €5257EUR$5,950USD£4,551GBP
- Report
- May 2021
- 250 Pages
Global
From €5257EUR$5,950USD£4,551GBP
- Report
- May 2024
- 166 Pages
Global
From €2209EUR$2,500USD£1,912GBP
- Report
- July 2023
- 110 Pages
Global
From €3976EUR$4,500USD£3,442GBP
- Report
- May 2024
- 200 Pages
Global
From €3667EUR$4,150USD£3,174GBP
- Report
- August 2024
Global
From €4374EUR$4,950USD£3,786GBP
- Report
- January 2023
- 103 Pages
Global
From €4374EUR$4,950USD£3,786GBP
- Report
- September 2022
- 62 Pages
Global
From €4374EUR$4,950USD£3,786GBP
- Report
- January 2023
- 343 Pages
Global
From €4418EUR$5,000USD£3,824GBP
- Report
- April 2025
- 184 Pages
Global
From €3976EUR$4,500USD£3,442GBP
- Report
- April 2025
- 182 Pages
Global
From €3976EUR$4,500USD£3,442GBP
- Report
- March 2025
- 182 Pages
Global
From €3976EUR$4,500USD£3,442GBP
From €3092EUR$3,500USD£2,677GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3092EUR$3,500USD£2,677GBP
- Report
- January 2025
- 140 Pages
Asia Pacific
From €3534EUR$4,000USD£3,059GBP
- Report
- October 2024
- 134 Pages
North America
From €3534EUR$4,000USD£3,059GBP
- Report
- July 2024
- 182 Pages
Global
From €3976EUR$4,500USD£3,442GBP
- Report
- June 2024
- 130 Pages
North America
From €3534EUR$4,000USD£3,059GBP
- Report
- May 2024
- 182 Pages
Global
From €3976EUR$4,500USD£3,442GBP
- Report
- May 2024
- 182 Pages
Global
From €3976EUR$4,500USD£3,442GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more